Selloff in Highly Priced Tech Stocks Is Pressuring Hedge Funds That Piled In


Novavax: Covid-19 Vaccine Gathering Momentum

Novavax (NVAX) investors have had to be patient, as delays have seen its Covid-19 vaccine lag competitors’ offerings. However, recently the vaccine has been showing evidence it could still play a prominent role in the ongoing global fight against the coronavirus. On Wednesday, the company announced two positive developments. First off, the biotech announced that NVX-CoV2373 has been granted emergency use authorization (EUA) in the Philippines, where it will go to market under the brand name COVO

Leave a Reply

Your email address will not be published. Required fields are marked *